Back to Basics: Designing digital patient services
|2nd July 2015
Head of Customer Experience Elisa del Galdo talks through the key considerations for pharma companies when designing and delivering digital patient services from a customer experience perspective.
As pharma marketing departments increasingly look towards digital services and solutions, there are a number of important considerations that companies cannot afford to neglect. Understanding client objectives should be the first port of call. When talking about innovation in marketing, the creation of digital services and multi-platform offerings often comes up. There has been a great deal of innovation applied to the provision of digital services and solutions within the pharmaceutical industry, in spite of the unique challenges created by strict regulations on the marketing of medical products. That said, the design and development of customer-focused services and solutions is a relatively new approach in this sector.
To read more, download the full PDF of this article, as it appeared in the IPT Online - Innovations in Pharmaceutical Technology June 2015 issue.
Precision paediatrics: Treating patients with CAR-T
|9th July 2019
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy for the first patient in Europe, and how the centre of excellence has adapted to make precision medicine a reality
What does it mean to be an agile organisation
|27th June 2019
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market.
Battling breast cancer with precision medicine (Part 2)
|20th June 2019
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives his side of the story and explains how industry can help oncologists treat more patients with targeted therapies.